Sun Pharmaceuticals Industries Ltd, one of India's leading pharmaceutical companies, received a significant legal victory in the United States on Thursday, April 10, 2025, after the US Court of Appeals for the Federal Circuit vacated a preliminary injunction that had previously halted the launch of Leqselvi (deuruxolitinib). This move paves the way for Sun Pharma to proceed with the launch of its drug, which is developed for the treatment of severe alopecia areata, a condition that causes patchy hair loss.

Background: The Legal Battle

The legal journey began when Sun Pharma filed a challenge against an injunction issued by the US District Court in November 2024. That injunction had prevented the company from launching Leqselvi in the US market. Sun Pharma had originally filed its challenge on August 1, 2024, expressing disagreement with the US District Court's ruling and its intent to appeal the decision.

The dispute primarily revolves around a litigation initiated by Incyte Corporation, a biopharmaceutical company that has interests in similar therapeutic domains. Despite the setback in November, Sun Pharma remained resolute and continued with its legal challenge. Their appeal reached the Federal Circuit, which held oral arguments earlier in 2025.

On April 10, the appellate court ruled in favour of Sun Pharma, stating that the preliminary injunction was vacated, thereby allowing the company to move forward with its product plans effective immediately.

What is Leqselvi?

Leqselvi (deuruxolitinib) is a promising oral medication aimed at treating severe alopecia areata, an autoimmune condition that causes unpredictable and often irreversible hair loss. Alopecia areata affects a significant number of individuals globally, and the development of effective treatments has been a key focus within dermatological research.

The approval and launch of Leqselvi in the US market would provide a new therapeutic option for patients suffering from this condition and further solidify Sun Pharma’s presence in the global dermatology and autoimmune treatment segment.

Sun Pharma’s Official Statement

While the court ruling offers relief, Sun Pharma has clarified that the litigation with Incyte is still ongoing. The company stated that it will disclose its detailed launch plans for Leqselvi in due course, depending on the evolving legal and regulatory landscape.

This cautious approach signals that while the court has cleared a major hurdle, Sun Pharma is navigating the situation carefully due to the ongoing complexities in the case.

Market Reaction and Share Price Movement

Despite this favourable court decision, Sun Pharma’s stock closed 2.17% lower on Wednesday at ₹1,651.75 apiece. This decline might reflect investor uncertainty around the continuing legal proceedings, or general market sentiment in the pharmaceutical sector.

In 2025 so far, Sun Pharma’s shares have seen a decline of 12.6%, making the recent court ruling a potentially positive catalyst that could reverse sentiment if followed by a successful product launch.

Ongoing Litigation with Incyte

It is important to note that the litigation between Sun Pharma and Incyte Corporation is far from over. While the injunction was vacated, the main lawsuit remains active, and its outcome could have implications on long-term commercial rights, possible licensing, or settlement negotiations.

The case has become an important one in the realm of pharmaceutical patent litigation, especially given the growing market for autoimmune disorder treatments. Legal outcomes in such cases often influence not only drug approvals and launches but also the stock performance and investor confidence in the involved companies.

Potential Implications for the US Market

The vacating of the injunction means Sun Pharma can now potentially launch Leqselvi in the US, a market that presents significant revenue opportunities. The United States is among the largest pharmaceutical markets globally, and Sun Pharma’s entry with an innovative alopecia treatment could generate substantial business.

This also puts Sun Pharma in direct competition with other pharmaceutical companies, including Incyte, that have similar drugs either in the market or pipeline. Market penetration, insurance coverage, pricing strategy, and clinical outcomes will play key roles in determining the drug's success.

Sun Pharma’s Growing Global Footprint

Sun Pharma has consistently worked towards expanding its footprint in international markets, particularly in the United States where it has a robust portfolio of generics, specialty medications, and research-driven therapies.

The launch of Leqselvi will further enhance its presence in the specialty medicine segment, which is higher margin and innovation-driven, compared to traditional generic drugs.

Investor Sentiment and Strategic Outlook

The latest court decision provides a ray of hope for Sun Pharma’s growth trajectory, especially as the company deals with regulatory hurdles and litigation challenges. Investors and analysts will now be watching for:

• Official launch timelines for Leqselvi

• Further court developments in the ongoing lawsuit

• Regulatory updates from the US FDA

• Potential market reception of the drug post-launch

If the launch proceeds smoothly, it could act as a turning point for the stock, especially given the current dip in performance.

Conclusion

The US Court of Appeals’ decision to vacate the injunction on the launch of Leqselvi is a major legal win for Sun Pharma, offering it the green light to proceed with its plans for introducing the alopecia treatment drug in the United States. While litigation with Incyte continues, the immediate opportunity for market entry presents a significant business advantage.

Investors, healthcare professionals, and market watchers will now await further updates from Sun Pharma regarding its launch plans and any developments in the lawsuit, which could influence the pharmaceutical landscape for autoimmune treatments significantly.

The Upcoming IPOs in this week and coming weeks are Aten Papers & Foam.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.